| Serial Number | 79386527 |
| Word Mark | MICROCAPS ADARE |
| Filing Date | Friday, July 21, 2023 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Monday, May 12, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Manufacturing services to the order and specification of others of drug dosage forms, drug compositions, drug formulations, drug delivery agents in the nature of tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines, injectables, aerosols, and sanitary products, all in the pharmaceutical and the veterinary fields; clinical manufacturing of drug compositions for others to support clinical trials |
| Description of Mark | The mark consists of the stylized capitalized wording "MICROCAPS" in white with aquamarine shading, on a rectangular background half in green on the left, fading to the other half in dark blue on the right. There are green ovals of color extending from the left into the blue on the right, and small white ovals of color throughout the green half. The wording "ADARE" in dark blue stylized capital letters appears below, with an aquamarine green circle above and encompassing the top of the second letter "A". |
| Goods and Services | Pharmaceutical, veterinary and sanitary products, namely, drug delivery agents in the form of specialized tablets, orally disintegrating tablets, minitablets, microtablets, minitablets and microtablets comprising multiparticulates, filled capsules, lozenges, powders, granules, granulates, sprinkles, sachets, patches, pads, suppositories, creams, gels, ointments, paste, emulsions, suspensions, syrups, elixirs, drops, liquids, skin lotions, vaccines and injectables used for the treatment of disorders or diseases in the gastrointestinal tract, in the digestive system, in the gut, in the immune systems, in the cardiovascular system, in the respiratory tract, in the blood, in the metabolism, in the nervous system, in the cognition, in the behavior, and in the reproductive tract, gastrointestinal infections, diarrhea, irritable bowel syndrome, inflammatory bowel syndrome disease, enterocolitis, enteritis, ulcerative colitis, cardiovascular disorders, hypertension, thrombosis, vasoconstriction, asthma, inflammation of respiratory tract, bronchoconstriction, thrombocythemia, hypertriglyceridemia, hypercholesterolemia, hyperlipoproteinemia, blood anemia, hypocalcemia, diabetes, diabetic peripheral neuropathy, dyskinesia, hyperkinetic movements, enzyme deficiency, pancreatitis, pancreatectomy, steatorrhea, cystic fibrosis, Paget's disease, bacterial infections, viral infections, fungal infections, osteoporosis, cancer, mucosal and systemic inflammation, functional disease, abdominal pain, allergy, obesity, muscle spasticity, spasms, convulsion, dysthymia, schizophrenia, degenerative dementia, Alzheimer's, stress, anxiety, depression, mood disturbance, sociability disturbance, sleep disturbance, psychological disturbance, attention deficit hyperactivity disorder, addiction, fibromyalgia, obsessive-compulsive disorders, pain, peripheral neuropathic pain, post-surgical pain, back-pain, osteoarthritis; inhalers for medical purposes sold filled with pharmaceutical, veterinary and sanitary preparations for treating asthma, pulmonary hypertension, inflammation of respiratory tract, bronchoconstriction, plasmodium infections and fungal infections |
| Indication of Colors claimed | The color(s) white, dark blue, and aquamarine green is/are claimed as a feature of the mark. |
| Goods and Services | Research and development services in the pharmaceutical and the veterinary fields; product design and development of pharmaceutical preparations including powder and granules for suspension in liquids, semisolid forms, solid forms, capsules, tablets, sachets, sprinkles; research and development in the area of drug delivery systems with customized release, taste masked release, controlled release; technological consultancy services in the field of new product development |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 29, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 29, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 29, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ADARE PHARMACEUTICALS s.r.l. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Event Date | Event Description |
| Thursday, December 28, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, December 29, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 2, 2024 | APPLICATION FILING RECEIPT MAILED |
| Saturday, March 9, 2024 | ASSIGNED TO EXAMINER |
| Thursday, March 14, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, April 2, 2024 | REFUSAL PROCESSED BY MPU |
| Tuesday, September 24, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, March 15, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, April 2, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, April 24, 2024 | REFUSAL PROCESSED BY IB |
| Tuesday, September 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, September 24, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 16, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, October 16, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, October 16, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, December 5, 2024 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Thursday, December 5, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, December 5, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, December 5, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, April 8, 2025 | EXPARTE APPEAL RECEIVED AT TTAB |
| Thursday, December 5, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, December 5, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, April 8, 2025 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| Tuesday, April 8, 2025 | EX PARTE APPEAL-INSTITUTED |
| Tuesday, April 8, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Friday, April 25, 2025 | ASSIGNED TO LIE |
| Monday, April 28, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, April 28, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, May 12, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, May 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Tuesday, May 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, June 13, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Monday, May 12, 2025 | NON-FINAL ACTION WRITTEN |
| Monday, May 12, 2025 | NON-FINAL ACTION E-MAILED |